HQ
HQH.US Tekla Healthcare Investors
- Market cap
- USD 1.23B
- P/E
- 4.8x
- P/B
- 1.08x
- ROE
- 9.0%
- Dividend yield
- 12.69%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2025.
Is HQH.US undervalued?
Graham numberHQH.US trades 52.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tekla Healthcare Investors fundamental analysis
No fundamental analysis for Tekla Healthcare Investors yet.
Tekla Healthcare Investors stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tekla Healthcare Investors
Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market po…
Full company profileTekla Healthcare Investors financial statements
Tekla Healthcare Investors annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.80M | 123M | 71.0M | -144M | 243M | 157M | -192M | 58.1M | 10.8M | 99.8M |
| Gross Profit | 4.80M | 123M | 71.0M | -144M | 243M | 157M | -192M | 58.1M | 10.8M | 99.8M |
| Operating Income | -6.28M | 121M | 69.2M | -145M | 241M | 155M | -194M | 56.3M | -220K | 98.6M |
| EBITDA | -49.7M | 126M | 73.3M | -142M | 243M | 161M | -191M | 56.3M | - | 98.6M |
| Net Income | -56.0M | 121M | 69.2M | -145M | 241M | 155M | -194M | 56.3M | 185M | 98.6M |
| EPS | -1.44 | 2.98 | 1.64 | -3.39 | 5.50 | 3.42 | -4.10 | 1.14 | 3.55 | 1.84 |
| Balance Sheet | ||||||||||
| Total Assets | 1.01B | 1.07B | 1.09B | 878M | 1.06B | 1.17B | 926M | 932M | 1.06B | 1.10B |
| Total Liabilities | 34.8M | 9.76M | 3.76M | 6.93M | 1.12M | 15.6M | 9.71M | 1.15M | 1.40M | 3.43M |
| Shareholders' Equity | 975M | 1.06B | 1.08B | 871M | 1.05B | 1.16B | 917M | 931M | 1.06B | 1.09B |
| Cash & Short-term Investments | 883.00 | 6.46M | 927.00 | 1.65M | 2.46M | 935.00 | 792.00 | 214.00 | 56.00 | 59.00 |
| Total Debt | - | - | - | - | 31.4K | 11.3M | 8.50M | - | - | - |
| Cash Flow | ||||||||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ratios | ||||||||||
| ROE | -5.7% | 11.5% | 6.4% | -16.7% | 22.9% | 13.4% | -21.2% | 6.0% | 17.5% | 9.0% |
| ROA | -5.5% | 11.4% | 6.4% | -16.6% | 22.8% | 13.2% | -21.0% | 6.0% | 17.4% | 9.0% |
| Net Profit Margin | -1,166.7% | 98.6% | 97.5% | - | 99.3% | 98.8% | - | 96.9% | 1,717.4% | 98.8% |
| Debt to Equity | - | - | - | - | 0.00x | 0.01x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tekla Healthcare Investors dividends
- Dividend yield
- 12.69%
- Forward dividend
- 2.72 USD
- Payout ratio
- -
- Ex-dividend date
- Nov 20, 2026
Who owns Tekla Healthcare Investors
- Insiders 0.00%
- Institutions 24.12%
- Public & others 75.88%
- Shares outstanding 57.2M
Tekla Healthcare Investors company profile
- Company name
- Tekla Healthcare Investors
- Ticker
- HQH.US
- Exchange
- USA Stocks
- Listed since
- Jan 5, 1988
- Sector
- Financial Services
- Industry
- Capital Markets
- Fiscal year end
- September
- Address
- 1900 Market Street, Philadelphia, PA, United States, 19103
- Phone
- 215 405 5700
- Website
- teklacap.com/hqh.html
About Tekla Healthcare Investors
Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
Tekla Healthcare Investors management
4- Dr. Daniel R. Omstead M.S, Ph.D.Portfolio Manager · born 1953
- Dr. Jason C. Akus M.B.A., M.D.Vice President of Research and Portfolio Manager
- Mr. Christopher F. Brinzey MBASenior Vice President of Research and Portfolio Manager
- Dr. Frank T. Gentile Ph.D.Senior Vice President of Research and Portfolio Manager · born 1962